# EDGAR Filing Document

**Accession Number:** 0001831828
**File Stem:** 0001193125-25-132736
**Filing Date:** 2025-6
**Character Count:** 47581
**Document Hash:** 0469e15659118f0075107d273c98c6b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-132736.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001193125-25-132736

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 47

**CONFORMED PERIOD OF REPORT**: 20250602

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001831828
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812744449
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40407
- **FILM NUMBER:** 251013085

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY, SUITE 1200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 650-770-0077

**MAIL ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY, SUITE 1200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 2, 2025

## Vera Therapeutics, Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40407** | **81-2744449** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **2000 Sierra Point Parkway, Suite 1200**<br> **Brisbane, California** | **94005** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

(650) 770-0077

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Class A common stock, $0.001 par value per share | VERA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.**  |

---

On June 2, 2025, Vera Therapeutics, Inc. (the "Company") announced positive 36-week data from the Company's ORIGIN Phase 3 clinical trial of atacicept in adult patients with immunoglobulin A nephropathy ("IgAN"). A copy of the press release is furnished as Exhibit 99.1. In connection with the data release, the Company compiled a presentation entitled "Origin Phase 3 Topline Results" (the "Presentation") that includes the week 36 data from the ORIGIN Phase 3 clinical trial referenced above. A copy of the Presentation is furnished as Exhibit 99.2. For important information about forward-looking statements, see the slide titled "Forward-Looking Statements" in Exhibit 99.2 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the "SEC") made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.**  |

---

As noted in Item 7.01, on June 2, 2025, the Company announced positive 36-week data from the Company's ORIGIN Phase 3 clinical trial of atacicept in adult patients with IgAN. Atacicept is the Company's potential best-in-class, disease-modifying dual inhibitor of the cytokines B-cell activating factor and a proliferation-inducing ligand. ORIGIN Phase 3 is an ongoing global, multicenter, randomized, double-blind, placebo-controlled clinical trial of 431 adults evaluating the efficacy and safety of atacicept in adult patients with IgAN. The primary efficacy endpoint was the change in 24-hour urine protein-to-creatinine ratio ("UPCR") compared to placebo at the 36-week interim analysis.

Participants treated with atacicept (n=103) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour UPCR, with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36. For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the ORIGIN Phase 2b trial. The safety profile of atacicept in this analysis was favorable, and comparable to placebo. The Company plans to share these results with the U.S. Food and Drug Administration (the "FDA") in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.

#### Next Steps
The ORIGIN Phase 3 trial will continue in a placebo-controlled blinded manner to evaluate the change in kidney function over two years as measured by estimated glomerular filtration rate and is expected to complete in 2027. The Company currently plans to submit a biologics license application ("BLA") for accelerated approval for atacicept in IgAN to the FDA in the fourth quarter of 2025, with a projected commercial launch, if approved, in 2026.

#### Forward-Looking Statements
Statements contained in this Current Report on Form 8-K regarding matters, events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the Company's expectations regarding the timing of submission of a BLA to the FDA and commercial launch, if approved, expansion of its development pipeline for atacicept, atacicept's potential to be a best-in-class treatment for patients with IgAN, the Company's expectations regarding the potential for B cell modulation through B-cell activating factor/A proliferation-inducing ligand dual inhibition to transform the treatment landscape for certain autoimmune diseases, the Company's anticipated presentations of clinical trial data, the Company's product candidates, strategy and regulatory matters and the Company's expectations regarding submitting a BLA for atacicept in IgAN and projected commercial launch. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "expects," "may," "plan," "potential," "will," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result

------

of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with the Company's business in general, the impact of macroeconomic and geopolitical events and the other risks described in the Company's filings with the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | [Press Release of Vera Therapeutics, Inc., dated June 2, 2025.](d916346dex991.htm) |
| 99.2 | [Slide presentation entitled "Origin Phase 3 Topline Results".](d916346dex992.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Vera Therapeutics, Inc.** | **Vera Therapeutics, Inc.** |
| Dated: June 2, 2025 |  |  |
|  | By: | /s/ Marshall Fordyce, M.D. |
|  |  | Marshall Fordyce, M.D. |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g916346g0601152436858.jpg)

**Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in** 

**ORIGIN Phase 3 Trial in Adults with IgA Nephropathy** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; patients receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continues* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *The safety profile of atacicept was favorable, and comparable to placebo* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 4Q 2025; ORIGIN 3 trial continues with two-year results expected in 2027* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Vera will host a conference call and webcast at 8:00 am ET on Monday, June 2* 

**BRISBANE, Calif., June 2, 2025 (GLOBE NEWSWIRE)** — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

Participants treated with atacicept achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36. For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the ORIGIN Phase 2b trial.<sup>1</sup> The safety profile of atacicept in this analysis was favorable, and comparable to placebo. Vera plans to share these results with the FDA in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.

"ORIGIN 3 is the first Phase 3 clinical trial in IgAN to demonstrate this magnitude of UPCR reduction compared to placebo at week 36. These results convincingly demonstrate the impact of atacicept to reduce proteinuria," said Richard Lafayette, M.D., F.A.C.P., Professor of Medicine, Nephrology and Director of the Glomerular Disease Center at Stanford University Medical Center, and a primary investigator for both ORIGIN 2b and ORIGIN 3.

"If approved, we believe that atacicept has the potential to advance the standard of care in IgAN as the first dual BAFF/APRIL inhibitor. We currently plan to submit a BLA for atacicept in IgAN to the FDA in the fourth quarter of this year, which may allow for US approval and commercial launch in 2026. We are grateful for the ongoing commitment of the study participants, their families and caregivers, the study investigators and staff, our research partners, and the Vera team for their commitment and dedication to this important research," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "Vera aspires to evolve the practice of kidney medicine with the hope that, one day, patients may no longer face a future of dialysis or transplantation. Vera is poised for potential commercial launch of atacicept in 2026 and to pursue development in additional indications in other autoimmune kidney diseases and beyond."

------

![LOGO](g916346g0601152436858.jpg)

"Patients with IgA nephropathy, as well as their families and care partners, suffer from clinical uncertainty and the horrible outcome of kidney failure. In addition to clinical signs and symptoms, IgAN has a devastating impact on quality of life and mental wellbeing. I'm thrilled with the progress that is being made in developing new treatments for patients," said Bonnie Schneider, Director and Cofounder of the IgA Nephropathy Foundation.

ORIGIN 3 is an ongoing global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial of 431 adults with IgA nephropathy. Participants were randomized 1:1 to atacicept 150 mg, self-administered at home via once weekly subcutaneous injection, or placebo. The primary efficacy endpoint was the change in 24-hour UPCR compared to placebo at the 36-week interim analysis. The trial continues in a placebo-controlled blinded manner to evaluate the change in kidney function over two years as measured by eGFR and is expected to complete in 2027.

For more information about the ORIGIN 3 clinical trial (NCT04716231), please visit http://www.clinicaltrials.gov.

**References** 

1. Barratt J, et al. JASN 2024

**About Atacicept** 

Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN, other autoimmune kidney diseases and lupus nephritis.

The ORIGIN Phase 2b clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further improvements in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR reflecting a profile consistent with that of the general population without IgAN.

------

![LOGO](g916346g0601152436858.jpg)

Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA's determination that, based on an assessment of data from the ORIGIN Phase 2b clinical trial, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Vera believes atacicept is positioned for best-in-class potential, targeting B cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical trials across different indications.

**About Vera** 

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com

**Forward-looking Statements** 

*Statements contained in this press release regarding matters, events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, atacicept's potential to be a best-in-class therapy for patients with IgAN, atacicept's potential as a treatment for indications beyond IgAN, Vera's expectations concerning other predefined endpoints in the Phase 3 ORIGIN trial, as well as the two-year data therefrom, Vera's plans to meet with, and submit a BLA for atacicept to, the FDA, and to potentially receive FDA approval for atacicept in IgAN and launch it commercially, and, in each case, the timing thereof, the potential for atacicept to bring value for patients and to the change the standard of care in IgAN, if approved, and other statements that are not historical fact. Because such statements are subject to risk and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipate," "believe," "expect," "plan," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later* 

------

![LOGO](g916346g0601152436858.jpg)

 *clinical trials, preliminary or interim results may not be predictive of final study results, risks and uncertainties associated with Vera's business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.* 

**<u>For more information, please contact:</u>**

**Investor Contact:** 

Joyce Allaire

LifeSci Advisors

212-915-2569

jallaire@lifesciadvisors.com

**Media Contact:** 

Debra Charlesworth

Vera Therapeutics

415-854-8051

corporatecommunications@veratx.com

## Exhibit 99.2

![](g916346ex99_2p1g1.jpg)

Exhibit 99.2 ORIGIN Phase 3 Topline Results June 2, 2025© 2025 Vera Therapeutics, Inc. Corporate Presentation.

------

![](g916346ex99_2p2g1.jpg)

Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. (we , us , our , or the Company). Statements in this presentation that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, atacicept's potential to be a transformational treatment for patients with IgAN and a first-in-class therapy, the Company's expectations regarding completing the pivotal Phase 3 ORIGIN 3 trial, the Phase 2 extension study in participants who completed the Phase 2b or Phase 3 ORIGIN trials and the Phase 2 PIONEER trial, atacicept's potential to be a transformational treatment for additional patient cohorts beyond those with IgAN, the Company's expectations regarding initiating clinical trials of atacicept for additional indications, the design and management of the Company's clinical trials, expectations regarding reporting results from such clinical trials and regulatory matters, including the timing and likelihood of success in obtaining drug approvals, the Company's market opportunity, atacicept's projected launch. Words such as "anticipate," "plan," "expect," "will," "may," "potential," "projected," "promise" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward- looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks related to the regulatory approval process, the potential that results of earlier clinical trials may not be obtained in later clinical trials, risks and uncertainties associated with the Company's business in general, the impact of macroeconomic and geopolitical events, and the other risks described in the Company's filings with the Securities and Exchange Commission. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation, and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Certain data in this presentation are based on cross-study comparisons and are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities or differences. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Investment in any securities described herein has not been approved or disapproved by the Securities and Exchange Commission or any other regulatory authority nor has any authority passed upon or endorsed the merits of the offering or the accuracy or adequacy of the information contained herein. Any representation to the contrary is a criminal offense. This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. 2© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p3g1.jpg)

• Founded in 2016 in San Francisco • Atacicept in-licensed in 2020: Potential first-in-class mechanism (dual BAFF/APRIL inhibitor) to transform treatment of autoimmune disease • IPO on Nasdaq May 2021; >$1B raised to date • IgAN Phase 3 read out in June 2025; market launch projected 2026, subject to US approval • Initiating PIONEER trial in broad IgAN and autoimmune kidney diseases this quarter • Led by a top-tier team, near-term target is to unlock pipeline-in-a-product potential APRIL, A proliferation-inducing ligand; BAFF, B cell activating factor; IgAN, immunoglobulin A nephropathy. 3© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p4g1.jpg)

Atacicept projected catalysts Catalyst 2025 2026 Phase 3 full enrollment Phase 3 primary endpoint IgAN 4Q BLA submission 1 Projected US launch IgAN Clinical results IgAN, PMN, Clinical results FSGS, MCD Vera holds worldwide, exclusive rights to develop and commercialize atacicept Based on management's current assumptions. 1. Subject to US FDA approval. BLA, Biologics License Application; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; PMN, primary membranous nephropathy. 4© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p5g1.jpg)

Strong Financial Position ~$590M ~63.7M Cash, cash equivalents, Shares outstanding (as of 5.01.25) and marketable securities (as of 3.31.25) 5© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p6g1.jpg)

B cell modulation via dual BAFF/APRIL inhibition represents a potential paradigm shift in how we treat patients with autoimmunity Autoimmune disease • Autoantigens and autoantibodies mediate Autoantibodies bind to autoantigens autoimmune disease BAFF • B cells are source of autoantibodies → B cell target cell of interest for therapeutic intervention • B cells fueled by two cytokines, BAFF and APRIL APRIL 1 TACI t =35 days 1/2 Atacicept receptor BAFF Kd • Rationally designed therapeutic of modern biotechnology 2 1.45 nM Fc domain of IgG1 • Native TACI-Fc fusion: soluble protein binds BAFF and APRIL with APRIL Kd nanomolar potency 2 0.672 nM • Offers the promise of precision modulation of B cells and autoantibodies Fc, fragment crystallizable; IgG1, immunoglobulin G1; Kd, dissociation constant; TACI, transmembrane activator and calcium-modulator and cyclophilin ligand. 1. Willen D, et al. Eur J Drug Metab Pharmacokinet 2020;45(1):27-40; 2. Vera data on file. 6© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p7g1.jpg)

Inhibition of immune complex formation in IgAN offers the potential to avoid end stage kidney disease over a patient's lifetime 80 5-year mean mortality 72 in ESKD comparable 60 to 3 most prevalent 59 cancers in US 40 36 20 9 0 Lung ESKD Colorectal Breast Cancer Cancer Cancer ESKD, end stage kidney disease. 1. US CDC Cancer Statistics; 2. Thurlow JS, et al. Am J Nephrol 2021 (data for ESKD resulting from all kidney disease). 7© 2025 Vera Therapeutics, Inc. Corporate Presentation 1,2 5-Year % Mortality in US

------

![](g916346ex99_2p8g1.jpg)

Robert M. Brenner, M.D. Chief Medical Officer 8© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p9g1.jpg)

Lead opportunity: IgAN is a disease of B cell origin with kidney pathology B Cell Activation Formation of Circulating Immune Complexes Immune Complex Deposition Leading to Glomerulonephritis and Kidney Damage Autoantigen (Gd-IgA1) BAFF TACI B cell Glomerulus APRIL Autoantibody (anti-Gd-IgA1) 1 2 3 4 5 BAFF and APRIL are Activated B cells produce …forming …which deposit in the …and progressive upregulated and autoantigen (Gd-IgA1) and immune mesangium, resulting in kidney injury with activate B cells via autoantibodies (anti-Gd-IgA1)… complexes… glomerular inflammation hematuria, proteinuria, the TACI receptor (nephritis)… and eGFR decline eGFR, estimated glomerular filtration rate; Gd-IgA1, galactose-deficient immunoglobulin A1. Cheung CK, et al. Frontiers Nephrol 2024. 9© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p10g1.jpg)

We believe an ideal IgAN disease modifying therapy would be expected to… Reduce immune complexes Resolve inflammation (Gd-IgA1) (hematuria) Reduce proteinuria Stabilize eGFR 10© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p11g1.jpg)

Phase 2b long-term results consistent with IgAN disease modification Including eGFR profile consistent with the general population of -1 mL/min/year Reduction in Gd-IgA1 Resolution of hematuria 0 0 -15 -20 -30 -40 -45 -60 -75% -60 -80 -66% -75 -100 0 12 24 36 48 60 72 96 0 12 24 36 48 60 72 84 96 Week from First Atacicept Dose Week from First Atacicept Dose n= 111 108 78 107 79 29 77 74 n= 63 62 60 60 61 61 43 41 40 Reduction in proteinuria eGFR stabilization 0 10 5 -20 Slope 0 -0.6 mL/min/year -40 -5 2 Annualized eGFR slope of -0.6 mL/min/1.73 m per year -52% Mean eGFR change from baseline -60 -10 0 12 24 36 48 60 72 84 96 0 12 24 36 48 60 72 84 96 Week from First Atacicept Dose Week from First Atacicept Dose n=113 110 107 109 109 108 78 74 75 n=112 110 108 108 109 108 78 76 75 Atacicept group includes all participants receiving any atacicept dose at each timepoint, with baseline (BL) defined as the last available measurement prior to the first dose of atacicept. Data from weeks 0 to 60 includes participants who switched from placebo to atacicept. 1. Percentage changes from BL computed using FDA-endorsed mixed-effects modeling; 2. Percentages represent change from BL in number of participants with hematuria at each visit divided by number with BL hematuria; 3. Changes from BL in eGFR analyzed using mixed-effects model for repeated measures analysis, and least-squares estimation and standard error (SE) estimated directly from model; eGFR slope analyzed using mixed-effects model with random intercept and random slope, and mean slope and SE estimated directly from model. Barratt J, et al. JASN 2024. UPCR, urine protein to creatinine ratio. 11© 2025 Vera Therapeutics, Inc. Corporate Presentation Mean ± SE % Change from BL Mean ± SE % Change from BL 1 1 in UPCR in Gd-IgA1 Mean ± SE Change from Change from BL 3 2 2 BL in eGFR, mL/min/1.73m in % Participants (95% CI)

------

![](g916346ex99_2p12g1.jpg)

ORIGIN Phase 3 Study Design Double-Blind Treatment Open-Label Extension Placebo Atacicept 150 mg SC QW Atacicept 150 mg SC QW 156 Week 0 36 104 1° Endpoint 2° Endpoint UPCR: n=203 eGFR: n=431 Fully enrolled Key Inclusion Criteria Key Endpoints • Patients ≥18 years old with biopsy-proven • Primary efficacy: UPCR-24h at week 36 IgAN and high risk of disease progression to support potential accelerated approval • Stable and optimized RASi for ≥12 weeks, – >90% power at week 36 use of SGLT2i allowed • Key secondary: eGFR change up to week 104 • UPCR-24h ≥1.0 g/g or UP ≥1.0 g per 24h – 90% power for eGFR Δ 4 mL/min at week 104 2 • eGFR ≥30 mL/min/1.73 m • Safety • Blood pressure ≤150/90 mmHg • Operational efficiency leveraging similar trial design and worldwide sites as ORIGIN 2b • Same self-administered SC formulation and dose as used in ORIGIN 2b RASi, renin-angiotensin system inhibitor; SC, subcutaneous; SGLT2i, sodium-glucose cotransporter-2 inhibitor. ClinicalTrials.gov NCT04716231. 12© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p13g1.jpg)

ORIGIN Phase 3 interim analysis set participant disposition 1 203 randomized and treated 106 atacicept 97 placebo 7 discontinued treatment 13 discontinued treatment Treatment 99 (93%) 84 (87%) ongoing 1. 204 participants were randomized, 1 participant was not treated. 13© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p14g1.jpg)

Demographics and baseline characteristics of ORIGIN 3 and ORIGIN 2b ORIGIN 3 Interim Analysis Set ORIGIN 2b Atacicept Placebo Total Total n=106 n=97 n=203 N=116 Age, median (range), y 40 (18, 72) 39 (19, 70) 40 (18, 72) 37 (18, 67) Male sex, n (%) 57 (54) 58 (60) 115 (57) 69 (59) Race, n (%) White 46 (43) 42 (43) 88 (43) 62 (53) Asian 59 (56) 52 (54) 111 (55) 51 (44) Black or African American 0 1 (1) 1 (0.5) 0 Native Hawaiian or other Pacific Islander 0 1 (1) 1 (0.5) 1 (1) Other/not reported 1 (1) 1 (1) 2 (1) 2 (2) Hispanic/Latino ethnicity, n (%) 14 (13) 6 (6) 20 (10) 4 (3) 2 eGFR, mean ± SD, mL/min/1.73 m 65 ± 28 65 ± 29 65 ± 28 63 ± 27 UPCR by 24h urine, mean ± SD, g/g 1.7 ± 0.9 1.8 ± 1.2 1.7 ± 1.0 1.6 ± 0.9 Time since biopsy, mean ± SD, y 2.5 ± 2.6 2.5 ± 2.4 2.5 ± 2.5 2.8 ± 2.8 SGLT2i use, n (%) 59 (56) 49 (51) 108 (53) 16 (14) 14© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p15g1.jpg)

ORIGIN Phase 3 UCPR results at week 36 1 Deeper reduction than observed in Phase 2b (35%) 15 Δ 42% p<0.0001 Atacicept, n=103 Placebo, n=95 0 -7% -15 -30 -45 -46% -60 Other prespecified endpoints achieved similar or better results compared to those observed in 2 ORIGIN Phase 2b (per FDA guidance, Vera is not sharing eGFR results at this time) 1. Lafayette R, et al. Kidney Int 2024; 2. Barratt J, et al. JASN 2024. 15© 2025 Vera Therapeutics, Inc. Corporate Presentation Mean ± SE % Change from baseline in UPCR

------

![](g916346ex99_2p16g1.jpg)

The safety profile of atacicept was favorable, and comparable to placebo Atacicept Placebo Total Participants, n (%) n=214 n=214 n=428 Adverse events 127 (59) 107 (50) 234 (55) 1 Serious adverse events 1 (0.5) 11 (5) 12 (3) 2 Adverse events leading to drug discontinuation 2 (1) 8 (4) 10 (2) Adverse events of infections and infestations 68 (32) 60 (28) 128 (30) Serious or severe infections and infestations 0 3 (1) 3 (1) Opportunistic infections 0 0 0 3 Study drug related adverse events 63 (29) 22 (10) 85 (20) 4 Adverse events associated with injection site reactions 51 (24) 11 (5) 62 (14) Hypersensitivity reactions 8 (4) 14 (7) 22 (5) Adverse events leading to death 0 0 0 Analysis of safety population (all participants randomized and treated) as of interim data cut on 15-May-2025. 1. Atacicept: cholecystitis; Placebo: gastroenteritis, lower respiratory tract infection, pneumonia, pyelonephritis, IgA nephropathy, renal impairment, acute myocardial infarction, transplant rejection, hyponatremia, osteonecrosis, ovarian epithelial cancer, carotid artery aneurysm, hypertension, acute cholecystitis. Participant incidence = 0.5% for each serious adverse event. 1 placebo serious adverse event was deemed related to study drug. 2. Discontinuations in the 2 atacicept participants were due to eczema and erythema. 3. Majority were mild to moderate injection site reactions that did not lead to discontinuation. 4. Injection site reactions among atacicept recipients were largely characterized by injection site erythema, bruising, and pruritis. 16© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p17g1.jpg)

Next steps and acknowledgements • Full results to be submitted for presentation at ASN and peer-reviewed publication, anticipated 4Q 2025 • Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway • Vera currently plans to submit a BLA for accelerated approval to the US FDA in 4Q 2025 • ORIGIN 3 trial continues; two-year results expected in 2027 These promising results would not be possible without the study participants, their families and caregivers, the study investigators and staff, our research partners, and the Vera team for their commitment and dedication to this important research ASN, American Society of Nephrology. 17© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p18g1.jpg)

Matt Skelton Executive Vice President, Commercial 18© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p19g1.jpg)

Estimated IgAN Epidemiology in 2032 1 US IgAN Prevalence: ~0.04% of US Population (360.5M) + ~40K Low Risk ~160K 2 (~24% of patients) + ~30K Moderate Risk 2 (~20% of patients) ~90K High Risk 2 (~56% of patients) Phase 3 population Phase 2 study ongoing BAFF/APRIL inhibition Patient counts rounded to nearest 1,000. 1. ClearView Partners Analysis; 2. Pitcher D, et al. Clin J Am Soc Nephrol 2023. Low risk assumed to be 0–0.44 g/g UPCR, moderate risk assumed to be 0.44–0.88 g/g, high risk assumed to be >0.88 g/g; percentage of patients per proteinuria category in study population 1 applied to estimated US IgAN prevalence. 19© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p20g1.jpg)

Nephrologists are spread across multiple sites of care, with office-based settings expected to be the focus of the most growth in the market Key Nephrology Call Points Rare Common CKD Acute Causes of CKD Causes of CKD Complications Kidney Injury Primary Glomerular Anemia SHPT Bypass Transplant Diabetes Disease Hyperphosphatemia Sepsis (ie, IgAN, pMN) Hypertension Hyperkalemia Toxins Nephrology Office Nephrology Office Dialysis Clinic/Office Inpatient Inpatient/Nephrology Office Projected market growth +++ ++ +-- High unmet need, premium Large patient Large market size with High unmet need, with Lack of innovative pricing potential, population with effective treatments, though no therapies beyond entrenched players, emergence of innovative enduring unmet need lack of recent innovation supportive care and increasing assets in development prevalence of ESKD CKD, chronic kidney disease; SHPT, secondary hyperparathyroidism. 20© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p21g1.jpg)

Atacicept profile performed well in survey with nephrologists • ORIGIN 2b 96-week results associated with nephrologists' • Nephrologists cite identifying awareness of atacicept, highlighted by strong performance appropriate patients for IgAN therapy across key metrics as key challenge and unmet need — Unaided awareness of atacicept and BAFF/APRIL inhibitors • With expanding therapeutic landscape increased—higher than APRIL-only mechanism of action for IgAN, treatment strategies are evolving to incorporate newer — More nephrologists prefer dual BAFF/APRIL vs APRIL-only therapies earlier in treatment algorithm MOA attributing dual action as addressing source of disease and at lower proteinuria thresholds and clinical data presented • Anticipated updated KDIGO — Nephrologists are increasingly impressed with potential guidelines are likely to foster further advancement offered by atacicept for IgAN patients evolution of IgAN treatment paradigm Spherix Realtime Dynamix US IgAN Q4 2024 (N=100 nephrologists), page 4. 21© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p22g1.jpg)

Nephrologists viewed atacicept as a desirable pipeline therapy for IgAN Most Desired IgAN Pipeline Agent % of familiar respondents (rated familiarity of product >3 on a 10-point scale) Most desired 2nd most desired 3rd most desired Rank top 3 73% 68% 16% 12% 48% 43% 26% 37% 18% 35% 18% 14% 16% 10% 14% 30% 15% 6% 20% 14% 15% 6% 7% atacicept sibeprenlimab povetacicept zigakibart ravulizumab IONIS-FB-LRx n=73 n=65 n=56 n=61 n=71 n=50 Considering the pipeline agents listed below, please rank order the TOP THREE that you would most like to see approved for use in IgAN. \| Why did you rank [XX] as your most preferred IgAN therapy in development? Spherix Realtime Dynamix US IgAN Q4 2024, page 17. 22© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p23g1.jpg)

Atacicept product profile is compelling to nephrologists Factor Rationale Atacicept eGFR stabilization (Ph2b data) Key driver of preference / potential use Mechanism of action / disease-modifying HCPs find this attribute compelling; Gd-IgA1 reduction therapy serves as evidence for academic clinicians Availability of long-term (96 week) data HCPs note that atacicept can potentially reduce number of treatments needed to delay dialysis / kidney failure Appropriate for patients with >1 g/g This patient type identified as appropriate for treatment UPCR, eGFR decline of 2.5 mL/min/y from patient case exercise Other biopsy findings, hematuria not While these may increase motivation to prescribe, required to prescribe atacicept HCPs are willing to prescribe without these Source: Primary Market Research, N=15 Nephrologists (11/2024). 23© 2025 Vera Therapeutics, Inc. Corporate Presentation Perceived Impact

------

![](g916346ex99_2p24g1.jpg)

Premium pricing in the IgAN space 1 Annual Prices for Approved IgAN Therapies $566,500 $162,500 $158,716 $151,259 Filspari Tarpeyo Vanrafia Fabhalta 1. As of May 30, 2025. \*Price for Tarpeyo reflects the 9-month recommended course of treatment. Full 12 month course of treatment would be $213,010. 24© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p25g1.jpg)

IgAN market and atacicept have many hallmarks of an attractive commercial opportunity IgAN Market Atacicept • We believe the nephrology market is ripe for • Potentially differentiating product attributes disruption due to low levels of approved • eGFR data highly valued with enthusiastic product saturation support from therapeutic experts and 3 • Large market with unmet need advisory boards 1 • Growing market with IgAN • Experienced commercial team in place and ready to execute on launch if approved 2 • Favorable payer mix • Exciting lifecycle opportunities 1. ClearView Healthcare Partners Analysis; 2. Bluepath Solutions research conducted in Q4 2024; 3. Spherix Realtime Dynamix US IgAN independent survey conducted in Q4 2024 and advisory boards conducted by Vera Therapeutics. 25© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p26g1.jpg)

Marshall Fordyce, M.D. Founder and Chief Executive Officer 26© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p27g1.jpg)

Atacicept has potential in multiple large markets, with an initial focus in nephrology MG DM Type 1 Other Potential Future Indications AIHA APS CAD Hematology ITP Sjogren's SLE SSc Rheumatology IgAN PMN FSGS, MCD LN 1 Nephrology AIHA, autoimmune hemolytic anemia; APS, antiphospholipid syndrome; CAD, cold agglutinin disease; DM, diabetes mellitus; ITP, immune thrombocytopenia; LN, lupus nephritis; MG, myasthenia gravis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis. 1. Atacicept is currently being evaluated in IgAN, PMN, FSGS, and MCD. 27© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p28g1.jpg)

Vera retains optionality to expand in autoimmune kidney disease & beyond US prevalence estimates ~230K Potential Future Indications 1-10 + ~70K Rheumatology Sjogren's, SLE, SSc, LN 1 ~160K Hematology Non-IgAN AIHA, APS, CAD, ITP autoimmune kidney disease Other PMN, FSGS, MCD DM Type 1, MG and Expanded IgAN BAFF/APRIL inhibition Vera Therapeutics corporate estimates for peak year prevalence based on 1. ClearView Healthcare Partners Analysis; 2. US Census 2023; 3. McGrogan A. Nephrol Dial Transplant 2011; 4. Couser ASN 2017; 5. Beck LH. N Engl J Med 2009; 6. Filler G. Am J Kidney Dis 2003; 7. Troyanov S. J Am Soc Nephrol 2005. 8. Hommos MS. Mayo Clin Proc 2017; 9. Hengel FE. N Engl J Med 2024; 10. Vivarelli M. Clin J Am Soc Nephrol 2017. 28© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p29g1.jpg)

PIONEER: Operationally efficient Phase 2 basket trial in expanded IgAN and anti-PLA2R & anti-nephrin podocytopathies Atacicept 150 mg SC QW Population 1, n ≤120 1 Expanded IgAN populations Week 0 52 Key Endpoints Population 2, n ≤40 • Primary: UPCR change Anti-PLA2R podocytopathy • Key secondary: eGFR change (PMN) • Exploratory: – Gd-IgA1 change – Change in percentage of participants with hematuria Population 3, n ≤40 – Change in anti-PLA2R antibodies Anti-nephrin podocytopathy – Change in anti-nephrin antibodies (MCD/FSGS) • Safety PLA2R, phospholipase A2 receptor. 2 1. 8 cohorts: adult IgAN with UPCR 1 to <5 g/g and eGFR 20 to <30 mL/min/1.73 m ; adult IgAN with UPCR 0.5 to 1.0 g/g; adult IgAN with UPCR ≥5.0 g/g; adult IgAN with UPCR 1 to <5 g/g and eGFR ≥30 mL/min/1.73m2; adult recurrent IgAN post kidney transplant; pediatric (10 to <18 y) IgAN with UPCR 0.5 to <5 g/g; adult IgA vasculitis nephritis; and pediatric IgA vasculitis nephritis (10 to <18 y). 29© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p30g1.jpg)

Vera Pipeline Research & Discovery Preclinical Clinical Marketed Phase 3 IgAN Atacicept PMN, FSGS, MCD Phase 2 Potential future autoimmune indications Potential future VT-109 autoimmune indications MAU868 BK virus Phase 2 Vera holds worldwide, exclusive rights to develop and commercialize 1 atacicept, VT-109 , and MAU868 1. These rights are for all therapeutic, prophylactic, diagnostic, and treatment uses in all fields. 30© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p31g1.jpg)

Q&A Marshall Fordyce, M.D. Founder and Chief Executive Officer Vera Therapeutics Robert M. Brenner, M.D. Chief Medical Officer Sean Grant Chief Financial Officer Matt Skelton Executive Vice President, Commercial Jonathan Barratt, Ph.D., F.R.C.P. Mayer Professor of Renal Medicine University of Leicester 31© 2025 Vera Therapeutics, Inc. Corporate Presentation

------

![](g916346ex99_2p32g1.jpg)© 2025 Vera Therapeutics, Inc.